T-I-H-I / Shutterstock.com
Market Herald logo

Subscribe

Be the first with the news that moves the market

Abundant Natural Health is developmenting a program which will focus on Australian and international distribution, brand awareness, and sales of its expanding magnesium product range.

Recently, ANH has secured two major Australian pharmacies to stock its products, with an emphasis on its magnesium-based range. ANH’s magnesium products sit on the shelves on 500 stores across Australia with the company focusing to increase this number to 5,000. 

ANH intends to invest in marketing strategies in order to increase coverage. These can include taking on brand ambassadors and optimising social media promotion. ANH attended China’s International Import Expo last November.

Representatives from Chinese distributors and Daigou groups expressed a strong interest in establishing a commercial relationship with ANH. For the remainder of 2019, ANH will rely on Daigou shoppers and the distribution in specialist pharmacies, gift shops and increased engagement with Asian social media.

In order to achieve this, a new Chinese website has been launched by the company. ANH will expand its magnesium product range and is focusing on developing magnesium lotion, bath sachets, a hand cream, and foot lotion.

This range is expected to appeal to the 175 million global sufferers of psoriasis, and 245 million sufferers of eczema/dermatitis. “By the end of the calendar year, we expect ANH will be selling six to eight natural magnesium and salt products across Australia and into China,” General Manager Shanan Birkin said.

Click here to view the full announcement

ABT by the numbers
More From The Market Herald

" Creso Pharma (ASX:CPH) signs potential partnership with Gotro for Sierra pet products

Creso Pharma (ASX:CPH) signs a heads of agreement with leading pet care distributor, Gotro Global, to…
The Market Herald Video

" Botanix Pharmaceuticals (ASX:BOT) accelerates Sofpironium Bromide NDA filing

Botanix Pharmaceuticals (ASX:BOT) has accelerated the submission of a New Drug Approval (NDA) for its Sofpironium…
The Market Herald Video

" ResApp (ASX:RAP) extends Medgate licence agreement in line with expansion plans

ResApp Health (ASX:RAP) has agreed to a 12 month extension to its commercial licence agreement with…

" Alterity Therapeutics (ASX:ATH) doses first patient in MSA trial

Alterity Therapeutics (ASX:ATH) doses its first patient in a clinical trial for a rare Parkinsonian disorder.